Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice

Table 5

Overall survival according to treatment for glioblastoma and age at diagnosis.

Treatment received	< 65 years of age at diagnosis		≥ 65 years of age at diagnosis		P-value^1
	n	Overall survival (months)	n	Overall survival (months)
Standard radiotherapy with concomitant and adjuvant temozolomide	38	18.9 (13.7-29.4)	15	16.4 (10.0-19.1)	0.14
Other treatment including temozolomide	32	12.5 (8.1-19.6)	45	6.5 (3.9-13.0)	0.0036
Other non-temozolomide treatment	55	10.2 (5.4-13.8)	76	5.5 (2.1-8.6)	0.0013
No treatment	12	1.9 (1.0-4.1)	34	1.5 (0.6-3.5)	0.40

Wilcoxon rank sum test used for comparing overall survival between the two age groups.